BrightInsight Named to Fierce Medtech's 2022 Fierce 15 List
SAN JOSE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today that the company has been named to Fierce Medtech’s 2022 Fierce 15. The Fierce Medtech’s Fierce 15 spotlights the most exciting startups in medtech.
“We are honored and excited to be named to Fierce Medtech’s 2022 Fierce 15 list and be among so many great innovators and startups in medtech,” said Kal Patel, M.D., CEO and Co-Founder of BrightInsight. “It was a hugely successful year for our company, made possible by the hard work, tenacity and dedication of our stellar team. And we expect 2023 to be an even bigger, better year. Digital has been maturing over the last five years—which has helped to drive adoption by biopharma and medtech. As we continue to invest in our BrightInsight platform and launch new products for our clients that deliver results, the future looks bright.”
Highlights from 2022 that made BrightInsight fierce:
“The annual special report showcases the most exciting medtech startups. This year’s honorees have demonstrated innovative solutions and have the potential to make a big impact in both the tech and healthcare industries. We applaud them and wish them success,” said Ayla Ellison, editor-in-chief of Fierce Biotech, Fierce Pharma and Fierce Healthcare.
About Fierce Medtech Fierce 15
Copyright © 2023 BrightInsight, Inc. BrightInsight and the BrightInsight logo are trademarks of BrightInsight, Inc. Other trademarks are the trademarks of their owners.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a8a62d66-1304-43ce-9db2-63b0dc81bb9a
Solutions Showcase Session: Redefining Technical Support Efficiency in a World Focused on Automation and AI
From Analyst to Implementer: Insights from an Insider
Cybersecurity Solutions Session